General Information of Drug (ID: DMGHN98)

Drug Name
GS-9901 Drug Info
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1 [1]
Cross-matching ID
PubChem CID
86763204
CAS Number
CAS 1640247-87-5
TTD Drug ID
DMGHN98

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting PI3-kinase delta (PIK3CD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAY 80-6946 DMLOS5R Follicular lymphoma 2A80 Approved [3]
Idelalisib DM602WT Chronic lymphocytic leukaemia 2A82.0 Approved [4]
Umbralisib DMYRBO1 Follicular lymphoma 2A80 Approved [5]
IPI-145 DMWA24P Follicular lymphoma 2A80 Approved [6]
Leniolisib DMWAD93 Stomach cancer 2B72 Approved [7]
Buparlisib DM1WEHC Breast cancer 2C60-2C65 Phase 3 [8]
INCB50465 DMZJP2T Diffuse large B-cell lymphoma 2A81 Phase 2 [9]
ME-401 DMK0UOY Follicular lymphoma 2A80 Phase 2 [9]
RP6530 DMYILGK Chronic lymphocytic leukaemia 2A82.0 Phase 2 [9]
Parsaclisib DMYBIFS Follicular lymphoma 2A80 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02258555) Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Gilead.
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
6 PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
7 Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
8 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.